Preventive visit

• Illness, injury, emergency visits, hospitalization, medications
• Caregiver concerns and review of systems
• Childcare and group-care illness exposure

• Breast milk, formula, cow’s-milk transition plan
• Food variety and texture, iron-rich foods, self-feeding, choking
• Milk type and volume, cup use, bottle weaning
• Juice, sweetened beverages, water and fluoride exposure

• Total sleep including naps; location and environment
• Bedtime routine and sleep concerns
• Temperament, regulation, irritability, separation anxiety, interaction

• Movement, communication, hearing, vision, social engagement
• Milestone progression and any loss of skills
• Caregiver concern warrants action regardless of schedule

• Household changes, stressors, support and childcare
• Food, housing and financial strain; IPV risk
• Caregiver mental health; risk-based ACE/SDOH assessment

• Eruption, brushing, varnish, bottle/bedtime feeding, dental home
• Car seat, water, falls, burns, poisoning, choking, firearms
• Smoke, nicotine, e-cigarette aerosol, caregiver substance impairment, lead and water

Waves bye-bye; plays games such as pat-a-cake.

Uses a special parent name; briefly pauses or stops at “no.”

Puts an object in a container; looks for a hidden object.

Pulls to stand; cruises; drinks from an open cup with help; pincer grasp.

Standardized parent-report screening at 12 months under the 2025 AAP clinical report.

AAP timing is nutrition-specific within 9–18 months; individual risk may move testing earlier or add testing.

Universal at 12 and 24 months for Medicaid-enrolled children; otherwise jurisdiction- and risk-dependent.

Test only when exposure, travel, household, immune, or epidemiologic risk is present.

Surveillance and risk assessment at every visit; no routine objective hearing screen at 12 months.

Examination-based assessment for all; instrument-based screening may be used when available at approximately ages 1–3.

Oral-health risk assessment; fluoride varnish after tooth eruption; dental home by age 1.

Surveillance at 12 months; no routine standardized developmental or autism-specific screen at this visit.

Dose 1 at 12–15 months; minimum age 12 months. Travel can alter timing.

Dose 1 at 12–15 months. Live vaccine; contraindicated in significant immunodeficiency.

Begin the 2-dose series at 12–23 months; dose 2 at least 6 months later.

Booster generally dose 4 at 12–15 months; product history and medical conditions can change the schedule.

Booster at 12–15 months; dose 3 or 4 depends on the product series.

Ordinarily due at 15–18 months; may be given at 12 months if at least 6 months have elapsed since dose 3.

Both have doses within a 6–18-month window; the record determines whether either is due.

Annual for children 6 months and older; number of seasonal doses depends on lifetime influenza-vaccine history.

Use corrected age when appropriate; individualize iron, growth, nutrition, ophthalmology and related follow-up.

Assess and refer without waiting for the routine schedule; abnormal growth needs nutritional evaluation and closer follow-up.

Apply the specific coverage, jurisdiction, exposure, feeding and epidemiologic rules described above.

Conditions can change growth, nutrition, vaccination, screening and referral; MMR and varicella are contraindicated in significant immunodeficiency.

May require accelerated vaccination; an MMR dose before 12 months for travel does not count toward the routine series.

Increase support and referral when caregiver mental health, substance use, IPV, food, housing or other needs affect the child.